Serological Study on Covid-19 Patients with a Focus on Cardiovascular Disease Marker

ABSTRACT

Background: The COVID-19 pandemic is caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) virus, which causes life-threatening illness and mortality. One of the most critical risk factors for severe COVID-19 and COVID-19 mortality is cardiovascular disease (CVD) that develops during infection. Objective: To determine the most common CVD that occurred during infection with COVID-19 patients and the link between CVD and Fate. Material and methods: A descriptive cross-sectional study was conducted between July 22 and April 10 2022 to describe the frequency of CVD among 100 COVID-19 patients, as well as to detect the serological cardiovascular markers with mortality rates of those patients who attended Al-Karama Teaching Hospital in Baghdad governorate, Al-Shafaa Hospital, and Al-Ramadi Teaching Hospital in Al-Anbar governorate. Blood samples from all of the patients were taken for cardiovascular serological markers, as per the manufacturer's instructions. Results: The mean age of the COVID-19 patients with CVD was 65 23.83.83 (83.0%). Thrombosis, heart failure, myocarditis, myocardial infarction or acute coronary syndrome, hypertension, myocardial injury, angina, and pulmonary embolism were found in 83 (83.0%) of the 100 confirmed COVID-19 cases using IgM antibodies against SARS-CoV-2 by ELIZA in the following frequencies 21, 9, 9, 7, 10, 11, 8, 5, and 3 respectively. ELIZA discovered COVID-19 patients with CVD utilizing IgG antibodies against SARS-CoV-2 in the remaining 17 cases (17.0%). Troponin-T, Ferritin, D-dimer, Leukocyte, B Urea, CRP LDH were 58.60 ±40.70, 368.36±265.75, 2523.05±1727.60, 15.00±7.67, 103.49±60.74, 33.13±35.74, 525.40±459.86, 4.11±2.13, respectively, among COVID-19 heart failure patients. Troponin-T, Ferritin, D-dimer, Leukocyte, B Urea, CRP LDH were 33.61±34.70, 481.20±181.89, 3361.15±14.26, 20.08±10.54, 76.71±28.02, 22.76±19.73, 536.35±798.14, 3.61±2.11, respectively among COVID-19 Myocarditis patients. Conclusion: There was no significant variation in mortality across the various CVD of COVID-19 cases, There were no significant differences in cardiovascular serological markers in different age groups of among CVD of COVID-19 cases. © 2022, ResearchTrentz Academy Publishing Education Services. All rights reserved.